Header Logo

Connection

Usman Baber to Medication Adherence

This is a "connection" page, showing publications Usman Baber has written about Medication Adherence.
Connection Strength

2.139
  1. Medication Nonadherence: A Challenging Conundrum for Clinical Trials, Patients, and Clinicians. J Am Coll Cardiol. 2022 08 23; 80(8):779-782.
    View in: PubMed
    Score: 0.783
  2. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). Eur Heart J. 2019 07 01; 40(25):2070-2085.
    View in: PubMed
    Score: 0.157
  3. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clin Res Cardiol. 2019 Jun; 108(6):643-650.
    View in: PubMed
    Score: 0.152
  4. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.139
  5. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). Am J Cardiol. 2017 Sep 15; 120(6):904-910.
    View in: PubMed
    Score: 0.137
  6. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. Int J Cardiol. 2017 Sep 15; 243:132-139.
    View in: PubMed
    Score: 0.136
  7. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.134
  8. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovasc Interv. 2016 07 25; 9(14):1461-9.
    View in: PubMed
    Score: 0.128
  9. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovasc Interv. 2016 07 11; 9(13):1349-57.
    View in: PubMed
    Score: 0.128
  10. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
    View in: PubMed
    Score: 0.126
  11. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ Cardiovasc Interv. 2020 04; 13(4):e008226.
    View in: PubMed
    Score: 0.041
  12. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovasc Interv. 2019 05 27; 12(10):983-992.
    View in: PubMed
    Score: 0.039
  13. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 04; 12(4):e007133.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.